-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, LogicBio Therapeutics announced the preliminary results of a Phase 1/2 clinical trial of its in vivo editing therapy LB-001 for the treatment of children with methylmalonic acidemia (MMA)
The press release states that this is the first clinical trial that has shown successful gene editing in children
In vivo gene editing achieved a major breakthrough this year.
The design of LB-001 uses an AAV vector to precisely insert a transgene expressing methylmalonyl-CoA mutase (MMUT) into the albumin gene locus of liver cells
The AAV vector also carries a transgene expressing albumin-2A.
▲The mechanism of action of LB-001 (picture source: LogicBio Therapeutics official website)
Reference materials:
[1] LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children.
(The original text has been deleted)